Keen global interest in the development of new drug modalities is being reflected in the trends of R&D support granted by a major South Korean state-run fund.
ADCs, New Modalities High On Korea State Fund’s Priorities
Oncology, Discovery-Stage Assets Lead
While oncology and discovery-stage assets accounted for the majority of R&D projects supported by a Korean state fund this year, new modalities such as ADCs and TPDs are emerging.
